Want to see SE:ORX full AI Analyst Report?
ORX Stock Chart & Stats
kr13.54
kr0.28(1.84%)
At close: 4:00 PM EDT
kr13.54
kr0.28(1.84%)
Day’s Range― - ―
52-Week Rangekr4.90 - kr36.00
Previous CloseN/A
Volume21.89K
Average Volume (3M)120.39K
Market Cap
kr181.94M
Enterprise Valuekr337.34M
Total Cash (Recent Filing)kr152.60M
Total Debt (Recent Filing)kr6.60M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Feb 04, 2027EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.69
Shares Outstanding35,127,056
10 Day Avg. Volume121,463
30 Day Avg. Volume120,394
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-9.78
Revenue Forecast (FY)kr19.00M
Bulls Say, Bears Say
Bulls Say
Low Current LeverageOrexo currently has low debt relative to equity, which reduces immediate solvency pressure and provides more flexibility than a highly leveraged structure. This balance-sheet support can help the company continue development and manage obligations while it works to restore profitability.
Pipeline And Regulatory ProgressProgress across several development programs creates multiple potential sources of future product, milestone, royalty or partnership income. Regulatory and clinical advancement also strengthens the platform’s strategic value, although benefits depend on successful approvals and commercialization.
Cost Restructuring And Risk SharingThe restructuring program is intended to lower the recurring cost base through staff and facility reductions, while partner contributions shift more development spending and risk away from Orexo. A leaner operating model could improve cash durability if revenue stabilizes.
Bears Say
Severe Revenue ContractionThe sharp decline in revenue indicates that Orexo’s current commercial base is substantially smaller than in the prior period. Combined with a very large net loss and negative operating margins, this weakens internal funding capacity and raises execution pressure on newer products.
Sustained Cash BurnPersistent operating and free-cash-flow losses reduce the funds available to finance clinical programs, regulatory work and corporate obligations internally. If the current burn rate continues, Orexo may remain dependent on external financing, asset monetization or successful partnering.
Volatile Capital StructureAlthough current debt is low, prior periods show that Orexo’s capital structure has changed materially and included negative equity. Continued losses could again weaken the equity base, limiting financial resilience and making future funding needs more consequential for shareholders.
Orexo AB News
ORX FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was kr4.90 and its highest was kr36.00 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is kr181.94M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Feb 04, 2027 which is in 102 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Oct 22, 2026. The company reported -kr2.744 earnings per share for the quarter, missing the consensus estimate of -kr2.1 by -kr0.644.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -1.9.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -kr2.744 in its last earnings report, missing expectations of -kr2.1. Following the earnings report the stock price went down -3.178%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in SE:ORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
ORX Company Deck
ORX Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call had a cautiously positive operational tone, with meaningful progress on Izipry, OX640, OX390, semaglutide, partnerships, and cost restructuring. However, the company continues to face substantial financial pressures, including low revenue, a SEK 118 million loss from continued operations, negative cash flow, reduced own cash of SEK 62 million, large historical Zubsolv-related obligations, and pending regulatory and partnering milestones. The number and importance of development milestones and the planned rights issue outweighed the challenges, supporting an overall positive sentiment.View all SE:ORX earnings summariesTechnical Analysis
Swedish Orphan Biovitrum AB
―
Camurus AB
―
AlzeCure Pharma AB
―
IRLAB Therapeutics AB Class A
―
Xspray Pharma AB
―